Phase 2 clinical TrialsAs previously announced, the Company has also completed registration form be evaluated in a phase 2 clinical trial in patients with locally advanced and / or metastatic pancreatic adenocarcinoma previously untreated with chemotherapy. 4 weeks, andceived the standard dose of gemcitabine plus glufosfamide. In addition to safety, the study is to investigate the efficacy of glufosfamide in combination with gemcitabine as by the response rate, duration of response, progression-free survival, overall survival, six-and twelve-month survival and change in serum tumor marker levels determined.
No new or unexpected adverse events were observed side effects, including renal failure. Toxicity and hematologic toxicity were similar to those observed in previous clinical trials glufosfamide the most common drug toxicities in the glufosfamide -treated patients were nausea and vomiting.Amat Y, Baratta MV, Bland ea, Watkins LR, Maier SF. Medial prefrontal cortex determined such stressors controllability affected behavior of and dorsal raphe nucleus of. Nat Neurosci. 2005 Feb 06,[ Epub ahead of print]. See press release: Oligopeptide Brain ‘Clear ‘satisfies fear of nimh.gov Board / Press / prsafetysignal.cfm.